Gli altri portali
Notizie
Comunicati Stampa
Social News
Offerte di Lavoro
Comunicati Stampa
Sezioni
Toggle navigation
Prima pagina
Elenco
Nuovo account
Inserimento
Pannello di controllo
Modifica password
Salute e Benessere
Seleziona Categoria
Tutte le Categorie
Agricoltura
Ambiente
Arte e Cultura
Cibi e Bevande
Economia
Editoria e Media
Elettronica
Energia
Fiere ed Eventi
Industria
Information Technology
Internet
Istruzione e Formazione
Moda
Non Profit
Politica e Istituzioni
Salute e Benessere
Scienza e Tecnologia
Servizi
Società
Spettacolo
Sport
Telecomunicazioni
Trasporti
Turismo
Varie
Italiano
Inglese
Spagnolo
DNA Nanotechnology Market worth $24.3 Bn by 2031 - Exclusive Report by…
DNA Nanotechnology Market Report Scope: DNA Nanotechnology Market Report Scope: DNA nanotechnology focuses on developing structures, devices, and systems at the nanoscale by harnessing the special characteristics of DNA molecules. Scientists can create highly precise and targeted nanostructures using DNA nanotechnology because DNA is a programmable building material. The potential of DNA nanotechnology in areas such as medical diagnostics, targeted medication administration, and the...
PR Newswire
21/03/2024
Mike Grey appointed Executive Chair of Theolytics' Board of Directors
This appointment comes at a pivotal time for Theolytics as the Company advances its lead asset - THEO-260 - into clinical trials in ovarian cancer this year. THEO-260 is an oncolytic adenovirus that has demonstrated compelling efficacy in preclinical studies, selected to be effective in stromal-rich solid tumors, combined with systemic, intravenous delivery potential. This appointment comes at a pivotal time for Theolytics as the Company advances its lead asset - THEO-260 - into clinical…
PR Newswire
21/03/2024
Comprehensive Metabolic Panel Testing Market to Reach $16.1 billion, Globally…
Request Sample of the Report on Comprehensive Metabolic Panel Testing Market Forecast - https://www.alliedmarketresearch.com/request-sample/A269963 Request Sample of the Report on Comprehensive Metabolic Panel Testing Market Forecast -https://www.alliedmarketresearch.com/request-sample/A269963 Prime determinants of growth Rise in prevalence of chronic diseases such as chronic kidney diseases, and diabetes, surge in geriatric population, and increase in advancements in diagnostic...
PR Newswire
21/03/2024
Alibaba.com Records Strong Growth in the Number of UK SME Buyers at This Year's…
March Expo is Alibaba.com's flagship online trade show, which aims to connect buyers and sellers from around the world, helping them to discover new products, services and possibilities to grow their business. March Expo is Alibaba.com's flagship online trade show, which aims to connect buyers and sellers from around the world, helping them to discover new products, services and possibilities to grow their business. In the UK, the most popular category by active buyers was the Skincare &...
PR Newswire
21/03/2024
Testosterone Replacement Therapy Market to Reach $2.9 billion Globally, by 2032…
Request Sample of the Report on Testosterone Replacement Therapy Market Forecast - https://www.alliedmarketresearch.com/request-sample/A08394 Request Sample of the Report on Testosterone Replacement Therapy Market Forecast -https://www.alliedmarketresearch.com/request-sample/A08394 Prime determinants of growth The market for testosterone replacement therapy is anticipated to experience substantial growth due to an increased prevalence of hypogonadism, heightened awareness regarding...
PR Newswire
21/03/2024
TreeFrog's Chief Scientific Officer & Co-founder, Maxime Feyeux, to present at…
Parkinson's Disease is the second most common neurodegenerative disease, caused by the progressive loss of neurons in the midbrain and other brain regions. Affecting 10 million people worldwide, it is a debilitating disease and there is an urgent unmet need as only symptomatic treatment is currently available. Symptoms usually appear when between 60-80% of dopaminergic neurons are already lost, so a regenerative medicine approach that can replace these neurons holds great potential…
PR Newswire
21/03/2024
XRP Healthcare Announces Strategic Partnership with Expogroup to Expand Presence…
In addition to its footprint in Africa and the Middle East, Expogroup has successfully hosted numerous events in emerging markets such as the CIS, Australia, Latin America, and India. With a robust network spanning more than 37 countries and managing over 25 trade fairs annually, Expogroup has demonstrated unparalleled expertise in facilitating international business connections and fostering economic growth. In addition to its footprint inAfricaand theMiddle East, Expogroup has...
PR Newswire
21/03/2024
Mission Therapeutics commences landmark trial of MTX325, a potential…
Mission Therapeutics has now completed dosing the first cohort of healthy volunteers in a multi-part, adaptive Phase I study evaluating safety, tolerability, pharmacokinetics and brain penetration of MTX325. Single ascending, multiple dose ascending and elderly healthy volunteer cohorts are planned in 2024, whereas Parkinson's Disease patients will be the focus of the trial in 2025. Mission Therapeutics has now completed dosing the first cohort of healthy volunteers in a multi-part, adaptive...
PR Newswire
21/03/2024
Essity completes divestment of its shares in Vinda
"Essity is now in better shape than ever. Following the divestment of Vinda the categories with the highest margins and lowest capital intensity account for a larger part of the company. The company's pulp consumption has halved, and we have a more attractive portfolio with higher profitability and lower volatility. The transaction reduced Consumer Tissue's share of net sales in 2023 from 41% to 33%. We look forward to continuing to grow a portfolio of more value-generating…
PR Newswire
21/03/2024
Sequential, a leading innovator in microbiome testing, is proud to announce a…
"Our partnership with Sequential seamlessly fits into our overarching strategy of ensuring thorough assessment of cosmetic performance across all dimensions with the latest technologies. Together, we're setting higher standards in skincare innovation for safer and effective products.", says Dr Pamela El Azzi, Marketing and Communication Manager - at Eurosafe. " Our partnership with Sequential seamlessly fits into our overarching strategy of ensuring thorough assessment of cosmetic…
PR Newswire
21/03/2024
CMR Surgical announces over 20,000 surgical cases completed using Versius
Over 20,000 surgical cases completed using VersiusThe versatile surgical robot Versius has now been used to perform over 20,000 surgical cases across seven specialties with data collected in the clinical registry and digital ecosystem to support sharing insights with surgeons and hospitalsThe small and portable design of Versius has supported over 75% of hospitals to use Versius across two or more specialties Reflecting the versatile design of Versius, the system has been most...
Nasdaq GlobeNewswire
21/03/2024
2024 outlook and pro forma financials
Novonesis provides outlook for 2024 with expected 5-7% organic sales growth and ~35% adj. EBITDA margin. Pro forma financials disclosed. Ester Baiget, CEO of Novonesis, said:“Today we provide key pro forma numbers as well as the first outlook for our new company. On a pro forma basis, 2023 was a solid year for Novonesis, including a Chr. Hansen that on a stand-alone basis delivered well in range of its latest full year outlook. We expect a solid 2024 performance with overall organic sales...
Nasdaq GlobeNewswire
21/03/2024
Hansa Biopharma publishes 2023 Annual and Sustainability Reports
Peter Nicklin, Chairman of the Board, Hansa Biopharma, said: "2023 was another important year for Hansa Biopharma. With a purpose grounded in scientific innovation, improving patient outcomes, and operating with the highest ethical standards, we look ahead to advancing critical science and delivering new medicines. The Board is confident in the strong and highly experienced team at Hansa and believes in its ability to deliver important drug development and commercial priorities." Peter…
PR Newswire
21/03/2024
Valneva to Present on its Chikungunya Vaccine IXCHIQ®, Participate in Multiple…
Saint-Herblain (France), March 21, 2024– Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, today announced it will present on its single-shot chikungunya vaccine, IXCHIQ ®, moderate a roundtable on the Zika and chikungunya viruses, and participate in a panel discussion on efforts to eradicate chikungunya at the 24th World Vaccine Congress, which will take place between April 1-4, 2024 at the Walter E. Washington convention center in Washington, D.C. The...
Nasdaq GlobeNewswire
21/03/2024
NMD Pharma Publishes Comprehensive Data Package for NMD670 in Science…
NMD Pharma Publishes Comprehensive Data Package for NMD670 inScience Translational Medicine ClC-1 is a chloride ion channel specifically expressed in skeletal muscle cells that normally dampens muscle fiber excitability and is involved in regulating muscle fiber excitability during exerciseClinical and preclinical data supports the notion that ClC-1 inhibition is a novel and highly translational therapeutic approach to improve symptoms in myasthenia gravis and, potentially, other...
Nasdaq GlobeNewswire
21/03/2024
IBA Reports Full Year 2023 Results
GROUP REVENUES UP 18.7% WITH OTHER ACCELERATORS UP 51.1%REBIT POSITIVE FOR FY23 WITH OTHER ACCELERATORS REBIT ALMOST QUADRUPLINGMEDIUM TERM GUIDANCE REITERATEDLouvain-la-Neuve, Belgium, 21 March 2024- IBA (Ion Beam Applications S.A), the world leader in particle accelerator technology, today announces its consolidated results for the 2023 financial year. (EUR 000)FY 2023FY 2022VarianceVariance %Total Net Sales428 717361 27067 44718...
Nasdaq GlobeNewswire
21/03/2024
Ultimovacs ASA: Annual Report 2023
Oslo, 21 March 2024:Ultimovacs ASA (“Ultimovacs”, ticker ULTI), a clinical-stage biotechnology leader in novel immunotherapeutic cancer vaccines, announces that the Board of Directors of Ultimovacs ASA has approved the Annual Report and ESG Report for 2023.Please find a PDF version of the annual report, as well as the report in European Single Electronic Format (ESEF), as attachments to this release. The Annual Report is also available at the company's website: www.ultimovacs.comThis...
Nasdaq GlobeNewswire
21/03/2024
SEQUANA MEDICAL SUCCESSFULLY RAISES EUR 11.5 MILLION IN AN EQUITY PLACEMENT
THIS ANNOUNCEMENT IS NOT FOR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN THE UNITED STATES OF AMERICA, AUSTRALIA, CANADA, JAPAN, SOUTH AFRICA OR ANY OTHER JURISDICTION WHERE TO DO SO WOULD BE PROHIBITED BY APPLICABLE LAW PRESS RELEASE REGULATED INFORMATION – INSIDE INFORMATION 21 March 2024, 07:00 am CET Ghent, Belgium,21March 2024 –Sequana Medical NV (Euronext Brussels: SEQUA)(the " Company " or " Sequana Medical "), a pioneer in the treatment of fluid overload in liver...
Nasdaq GlobeNewswire
21/03/2024
ONWARD® Medical Successfully Raises €20 Million in a Capital Increase by Way of…
NOT FOR DISTRIBUTION OR RELEASE, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, CANADA, AUSTRALIA OR JAPAN OR ANY OTHER JURISDICTION IN WHICH THE DISTRIBUTION OR RELEASE WOULD BE UNLAWFUL. OTHER RESTRICTIONS ARE APPLICABLE. PLEASE SEE THE IMPORTANT NOTICE AT THE END OF THE PRESS RELEASE. THIS PRESS RELEASE CONTAINS INSIDE INFORMATION WITHIN THE MEANING OF ARTICLE (7)(1) OF THE EUROPEAN MARKET ABUSE REGULATION (596/2014) Existing shareholders INKEF Capital and EQT Life Sciences...
Nasdaq GlobeNewswire
21/03/2024
Alvotech Reports Financial Results for Full Year 2023 and Provides a Business…
Total Revenues in 2023 were $93.4 million, up 10% from previous yearProduct Revenues in 2023 were $48.7 million, compared to $24.8 million in 2022, with Q4 2023 product revenues of $18.9 million, up by 37% from the same period last year Alvotech's Simlandi™ biosimilar to Humira® (adalimumab) was approved in the U.S. as the first high-concentration biosimilar with interchangeable status Sales of Alvotech's Jamteki™ biosimilar to Stelara® (ustekinumab) started in Canada with...
Nasdaq GlobeNewswire
20/03/2024
BerGenBio Announces Initiation of Phase 2a in First Line Non-Small Lung Cancer…
BERGEN, Norway, March 20, 2024 /PRNewswire/ -- BerGenBio ASA (OSE: BGBIO), a clinical-stage biopharmaceutical company developing novel, selective AXL kinase inhibitors for severe unmet medical needs, announced today it has initiated the Phase 2a portion of the BGBC016 clinical study of its selective AXL inhibitor bemcentinib in combination with standard of care therapy in first-line Non Small Cell Lung Cancer (NSCLC) patients harboring a STK11 mutation (STK11m). BERGEN, Norway,March 20,...
PR Newswire
20/03/2024
ONWARD® Medical Launches Capital Increase by Way of an Accelerated Bookbuild…
THIS PRESS RELEASE CONTAINS INSIDE INFORMATION WITHIN THE MEANING OF ARTICLE (7)(1) OF THE EUROPEAN MARKET ABUSE REGULATION (596/2014) The Capital Increase is aimed at institutional investors and certain founders, management and members of the Board of Directorsby way of an accelerated bookbuild offering through a Private Placement via the Joint Bookrunners as well as retail investors by way of a Public Offering in France via the PrimaryBid platform Existing...
Nasdaq GlobeNewswire
20/03/2024
ONWARD® Medical Launches Capital Increase by Way of an Accelerated Bookbuild…
THIS PRESS RELEASE CONTAINS INSIDE INFORMATION WITHIN THE MEANING OF ARTICLE (7)(1) OF THE EUROPEAN MARKET ABUSE REGULATION (596/2014) Capital increase by issuance of New Shares designed to secure funding for the ARC-IM ®and ARC-EX ®development and regulatory approval, to establish a commercial organization for the ARC-EX US launch, to build quality, operations and other infrastructure capabilities, and to fund working capital requirementsOffering for an indicative amount of €15...
Nasdaq GlobeNewswire
20/03/2024
EssilorLuxottica: Disclosure of Share Capital and Voting Rights Outstanding as…
Disclosure of Share Capital and Voting Rights Outstandingas of March 13, 2024(Pursuant to Article L.233-8 II of the French Commercial Code and articles 221-1 and 223-16 of the General Regulations of the Autorité des Marchés Financiers)Charenton-le-Pont, France (March 20, 2024 - 6:00 pm)– As of March 13, 2024, shares and voting rights outstanding of EssilorLuxottica, the global leader in the design, manufacture and distribution of ophthalmic lenses, frames and sunglasses, breaks...
Nasdaq GlobeNewswire
20/03/2024
Altri Comunicati
